Key facts
- Notable investors include NLC Health Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Rheumasense
- ·The full record, as it builds
Funding rounds
No funding rounds for Rheumasense are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rheumasense
Developer of a diagnostic technology designed to reshape chronic disease management and rheumatoid arthritis care. The company combines liquid chromatography-mass spectrometry (LC-MS) biomarker testing with machine learning analytics to deliver real-time, objective insights into rheumatoid arthritis (RA) disease activity, enabling clients to measure a specific, accurate, and quantitative view of disease levels.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2024
- Website
- rheumasense.com/
- Ownership
- Privately Held (backing)
Rheumasense doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rheumasense shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rheumasense in its N-PORT filings yet. We sweep new filings monthly.